| Toggle Summary
|
Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Reports Fiscal 2015 Fourth Quarter and Year End Financial Results and Business Updates
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Report First Quarter 2016 Financial Results and Business Updates on May 3, 2016
Management to host conference call
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Reports First Quarter 2016 Financial Results and Business Updates
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Positive Results From Phase IIB Trial of MIN-101 Monotherapy in Schizophrenia
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Positive Results in Phase IIA Trial of MIN-117 in Major Depressive Disorder
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Present at Jefferies 2016 Healthcare Conference on June 8, 2016
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Proposed Public Offering of Common Stock
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Pricing of Public Offering of Common Stock
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference June 21, 2016
|
View HTML
|
